<sup>131</sup>I治疗甲状腺肿瘤患者出院剂量指导水平分析

易艳玲; 卓维海

¹³¹I治疗甲状腺肿瘤患者出院剂量指导水平分析

易艳玲 , 卓维海

文章导航 > 国际放射医学核医学杂志 > 2008, 32 > 6: (372-375)

引用本文:

Citation:

¹³¹I治疗甲状腺肿瘤患者出院剂量指导水平分析

200032 上海, 上海市复大学放射医学研究所
基金项目:
国家自然科学基金(10675036)

Analysis of recommendations for radiation doses of release of thyroid cancer patient after ¹³¹I therapy

Institute of Radiation Medicine, Fudan University, Shanghai 200032, China

摘要: 常用于治疗甲状腺肿瘤的¹³¹I,发射高能量γ射线,用药量也较大,是核医学科中对医院工作人员、护工、患者亲属及公众产生最大外照射剂最的一种核素,为了限制其对相关人员外照射剂量,一般都需要有相应的控制措施。主要综述不同时期、不同国家或组织推荐的¹³¹I治疗甲状腺肿瘤患者的出院辐射防护剂量水平指导原则,并对指导原则的变化及差异作进一步分析。
- 碘放射性同位素 /
- 甲状腺肿瘤 /
- 辐射防护 /
- 出院剂量指导水平
Abstract: As the most common nuclide used to treat thyroid cancer, ¹³¹I, with high energy gamma rays, contributes the largest dose to medical staff, caregivers, relatives and the public because of its large amount of dosage in nuclear medical practice. Some control measures are required to limit the correlative persons' dose by its external exposure when the patients are released from the hospitals. This review will summarize the release criteria from hospitals of ¹³¹I therapy thyroid cancer patients between different countries or organizations in different periods. The variety of the release criteria is discussed.
- Iodine radioisotopes /
- Thyroid cancer /
- Radiation protection /
- Release criteria
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Firestone RB,Frank Chu SY,Shireley VS. Table of Isotopes CD-ROM[CD]. 8th ed. California:Lawrence Berkeley National Laboratory,1996:4362.
[2]	ICRP. Limits for the intake of radionuclides by workers[R].International Commission on Radiological Protection,Publication 30.Oxford,UK:Pergamon,1979.
[3]	Johansson L,Leide-Svegborn S,Mattsson S,et al. Biokinetics of iodine in man:refinement of current ICEP dosimetry models[J]. Cancer Biother Radiopharm,2003,18(3):445-450.
[4]	Siegel JA,Marcus CS,Sparks RB. Calculating the absorbed dose from radioactive patients:the line-source versus point-source model[J].J Nucl Med,2002,43(9):1241-1244.
[5]	ICRP. Release of patients after therapy with unsealed radionuclides[R]. International Commission on Radiological Protection,Publication 94. Stockholm,Sweden:Elsevier Ltd,2004.
[6]	International Atomic Energy Agery. Basic safety standards[R]. Vienna:International Atomic Energy Agery,1996.
[7]	International Atomic Energy Agery. Nuclear medicine resources manual[R]. Vienna; International Atomic Energy Agery,2006.
[8]	U S Nuclear Regulatory Commission. Regulatory guide 8.39:release of patients administered with radioactive materials[R].Washington DC:Office of Nuclear Regulatory Research,1997.
[9]	European Atomic Energy commanity. Expert group ex/art 31 guidance of radiation protection following iodine therapy concerning doses due to outpatients or discharged inpatients[R]. Brussels:European Atomic Energy commanity,1997.
[10]	European Commission. Radiation protection 97:Radiation protection following iodine-131 therapy (exposures due to out-patients or discharged in-patients[R]. Luxembourg:European Commission,1998.
[11]	European Thyroid Association. ¹³¹-I therapy for hyperthyroidism towards 2000[J]. Eur J Nucl Med,1996,23(4):BP13-BP15.
[12]	Australian radiation protection and nuclear safety agency. Recommendations:Discharge of patients undergoing treatment with radioactive substances[R]. Austraial:Australian radiation protection and nuclear safety agency,2002.
[13]	Muhammad W,Faaruq S,Matiullah,et al. Release criteria from hospitals of ¹³¹I thyrotoxicosis therapy patients in developing countries-case study[J]. Radiat Prot Dosimetry,2006,121(2):136-139.
[14]	潘自强,叶常青,张延生,等.GB18871-2002:电离辐射防护与辐射源安全基本标准[S].北京:中国标准出版社,2002.
[15]	Coover LR,Silberstein EB,Kuhn PJ,et al. Therapeutic ¹³¹I in outpatients:a simplified method conforming to the Code of Federal Regulations,title 10,part 35.75[J]. J Nucl Med,2000,41(11):1868-1875.
[16]	Al-Haj AN,Lagarde CS,Lobriguito AM. Patient parameters and other radiation safety issues in ¹³¹I therapy for thyroid cancer treatment[J]. Health Phys,2007,93(6):656-666.

[1]	成钊汀 , 谭建 . 分化型甲状腺癌术后患者¹³¹I治疗的辐射剂量与防护. 国际放射医学核医学杂志, 2014, 38(2): 110-116. doi: 10.3760/cma.j.issn.1673-4114.2014.02.010
[2]	冼嘉朗 , 吴菊清 , 卢建杏 , 欧阳伟 , 冯会娟 , 陈盼 , 王静 , 邓玉颖 , 陈艳莹 , 罗嘉欣 . 甲状腺乳头状癌患者术后首次¹³¹I治疗后辐射剂量率的影响因素及出院时间的探讨. 国际放射医学核医学杂志, 2020, 44(2): 73-80. doi: 10.3760/cma.j.issn.1673-4114.2020.02.001
[3]	杨珂 , 唐波 , 于夕荣 , 张巍 . 甲状腺癌¹³¹I治疗病房的辐射屏蔽计算与评价. 国际放射医学核医学杂志, 2015, 39(5): 405-406, 419. doi: 10.3760/cma.j.issn.1673-4114.2015.05.012
[4]	易婉婉 , 袁雪宇 , 蔡海东 , 刘瑾 , 张倩 , 范素云 , 吕中伟 . ¹³¹I治疗分化型甲状腺癌术后患者辐射剂量预测模型的研究. 国际放射医学核医学杂志, 2022, 46(2): 67-72. doi: 10.3760/cma.j.cn121381-202102004-00139
[5]	袁海娟 , 林主戈 , 吴春兴 , 陈宇导 , 周英伟 , 张峰 , 程木华 . ¹³¹I治疗分化型甲状腺癌患者体内残留辐射剂量及病房辐射剂量的监测分析. 国际放射医学核医学杂志, 2019, 43(5): 400-404. doi: 10.3760/cma.j.issn.1673-4114.2019.05.003
[6]	武含露 , 闫志华 , 李祥周 , 陈伟娜 , 贾静 , 崔丽萍 , 叶垚杉 , 刘阳 , 韩星敏 , 程兵 . 分化型甲状腺癌患者¹³¹I治疗后诊断性全身显像周围剂量当量率动态变化的研究. 国际放射医学核医学杂志, 2020, 44(4): 212-216. doi: 10.3760/cma.j.cn121381-201907038-00023
[7]	岳园芳 , 刘建井 , 尹国涛 , 戴东 , 徐文贵 . DTC患者¹³¹I治疗后左甲状腺素钠片最佳初始剂量预测模型探究. 国际放射医学核医学杂志, 2022, 46(4): 197-202. doi: 10.3760/cma.j.cn121381-202111005-00171
[8]	阮卓 , 陆克义 . 分化型甲状腺癌术后¹³¹I治疗对生殖系统的辐射影响. 国际放射医学核医学杂志, 2023, 47(7): 425-429. doi: 10.3760/cma.j.cn121381-202211024-00317
[9]	郭睿 , 李彪 . 钠碘同向转运体基因介导放射性碘治疗肿瘤的研究进展. 国际放射医学核医学杂志, 2010, 34(3): 147-151. doi: 10.3760/cma.j.issn.1673-4114.2010.03.005
[10]	刘建宇 , 朱宗平 , 石德道 , 郑飞波 . 放射性碘难治性分化型甲状腺癌去分化分子机制及再分化治疗的分子靶向药物. 国际放射医学核医学杂志, 2023, 47(2): 123-126. doi: 10.3760/cma.j.cn121381-202205003-00267

点击查看大图

计量

文章访问数: 1587
HTML全文浏览量: 192
PDF下载量: 3

¹³¹I治疗甲状腺肿瘤患者出院剂量指导水平分析

200032 上海, 上海市复大学放射医学研究所

收稿日期: 2008-10-29

基金项目: 国家自然科学基金(10675036)

关键词:

摘要: 常用于治疗甲状腺肿瘤的¹³¹I,发射高能量γ射线,用药量也较大,是核医学科中对医院工作人员、护工、患者亲属及公众产生最大外照射剂最的一种核素,为了限制其对相关人员外照射剂量,一般都需要有相应的控制措施。主要综述不同时期、不同国家或组织推荐的¹³¹I治疗甲状腺肿瘤患者的出院辐射防护剂量水平指导原则,并对指导原则的变化及差异作进一步分析。

English Abstract

全文HTML

参考文献 (16)

下载: 全尺寸图片幻灯片

返回文章

用微信扫码二维码

分享至好友和朋友圈

131I治疗甲状腺肿瘤患者出院剂量指导水平分析

Analysis of recommendations for radiation doses of release of thyroid cancer patient after 131I therapy

计量

出版历程

131I治疗甲状腺肿瘤患者出院剂量指导水平分析

English Abstract

Analysis of recommendations for radiation doses of release of thyroid cancer patient after 131I therapy

全文HTML

目录

¹³¹I治疗甲状腺肿瘤患者出院剂量指导水平分析

Analysis of recommendations for radiation doses of release of thyroid cancer patient after ¹³¹I therapy

¹³¹I治疗甲状腺肿瘤患者出院剂量指导水平分析

Analysis of recommendations for radiation doses of release of thyroid cancer patient after ¹³¹I therapy